Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 19, 2024
Product Development
An understudied dementia soon to get a pair of Phase II readouts
CervoMed and Cognition Therapeutics testing different therapeutic hypotheses in dementia with Lewy bodies
BioCentury | Sep 18, 2024
Product Development
Data from Merck, Daiichi could support first approval for HER3 ADC
In BioCentury’s latest clinical report, Merck-Daiichi product scores on PFS after setback at FDA, plus updates from Ascendis, Boehringer, Atea and more
BioCentury | Apr 2, 2024
Product Development
Neurology’s false choice: symptomatic vs. disease-modifying
A new theme in Alzheimer’s is aiming for early symptom relief PLUS long-term disease modification
BioCentury | Feb 21, 2024
Product Development
Rare disease spotlight: treating a facial muscular dystrophy at its root
As the most advanced FSHD programs aim to reduce muscle cell death, the next wave is targeting the disease’s genetic cause
BioCentury | Sep 1, 2023
Distillery Therapeutics
Inhibiting CD36 for SARS-CoV-2 E-induced platelet activation and thrombosis
BioCentury | Mar 31, 2023
Deals
March 30 Quick Takes: Scynexis deal gives GSK another anti-infective
Plus: AstraZeneca in-licenses CLDN18.2 asset from China’s KYM, updates from newly public biotechs Apollomics and GI Innovation and more
BioCentury | Jun 5, 2021
Targets & Mechanisms
Going beyond genetic medicines for muscular dystrophy
Muscular dystrophy programs in the clinic cover not only a range of muscle mechanisms but also anti-fibrotic and anti-inflammation ones
BioCentury | Jun 27, 2020
Product Development
BARDA no longer funding immunomodulators as support for the therapeutic class to treat COVID-19 grows
BioCentury | Jan 2, 2020
Company News
Jan. 3 Company Quick Takes: Illumina, PacBio call off deal; plus Innovax, Innate, J&J-Pulmatrix, Intrexon, Janssen-Provention
BioCentury | Mar 29, 2019
Targets & Mechanisms
Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment
A look at new and emerging targets at AACR 2019 and their mechanisms
Items per page:
1 - 10 of 131